Los Angeles Capital Management
ALT icon

Los Angeles Capital Management’s Altimmune ALT Stock Holding History

Los Angeles Capital Management’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-128,529
Closed -$523K – 2393
2025
Q4 		$523K Buy
+128,529
New +$560K ﹤0.01% 868
2025
Q3 		– Sell
-13,947
Closed -$54K – 1358
2025
Q2 		$54K Buy
+13,947
New +$75.5K ﹤0.01% 1298
2025
Q1 		– Sell
-31,197
Closed -$225K – 1083
2024
Q4 		$225K Sell
31,197
-35,340
-53% -$270K ﹤0.01% 1023
2024
Q3 		$409K Sell
66,537
-37,067
-36% -$251K ﹤0.01% 917
2024
Q2 		$689K Buy
+103,604
New +$765K ﹤0.01% 771

Other funds holding ALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Los Angeles Capital Management's ALT Position: Q1 2026 in Review

Los Angeles Capital Management sold out of Altimmune (ALT) in Q1 2026, closing a stake of 128,529 shares — an estimated $523K sold.

Los Angeles Capital Management first reported a position in ALT in Q2 2024 and held it in 5 quarters. The position peaked at $689K in Q2 2024. 173 funds tracked by Wall St. Rank hold ALT as of Q1 2026.

  • Los Angeles Capital Management reported no remaining Altimmune position as of Q1 2026 after selling out during the quarter.
  • Los Angeles Capital Management sold 128,529 Altimmune shares in Q1 2026, an estimated $523K.
  • Los Angeles Capital Management first reported a position in Altimmune in Q2 2024 and held it in 5 quarters.
  • Los Angeles Capital Management's Altimmune position peaked at $689K in Q2 2024.
  • 173 funds tracked by Wall St. Rank held Altimmune as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.